| Nov 13 |
Tectonic Therapeutic Inc. Reports Q3 2024 Results
|
| Nov 11 |
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
|
| Nov 7 |
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Oct 27 |
Tectonic Therapeutic Independent Director Acquires 7.0% More Stock
|
| Oct 22 |
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
|
| Sep 29 |
Wall Street Breakfast: The Week Ahead
|
| Sep 23 |
Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans
|
| Sep 19 |
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
|
| Aug 22 |
Tectonic draws bullish view at Wells Fargo on lead asset
|
| Aug 20 |
Tectonic Therapeutic to Participate in September Investor Conferences
|
